Biotech

All Articles

AN 2 one-halfs head count, stops stage 3 test after information let down

.AN2 Therapies is actually reviewing its company in response to dull midphase records, pledging to g...

Merck pays out $700M for bispecific, snooping autoimmune opening and odds to challenge Amgen in cancer

.Merck &amp Co. is actually paying $700 thousand ahead of time to challenge Amgen in a blood stream ...

Gilead pays out J&ampJ $320M to exit licensing offer for seladelpar

.With Gilead Sciences almost an FDA decision for its own liver ailment medicine seladelpar, the comp...

' All hands on deck' at Lilly as peers target excessive weight market

.CEO David Ricks may observe the companies establishing outdoors tents at basecamp behind Eli Lilly ...

Entero giving up workers, abandoning office and pausing R&ampD

.Bed Liquidators has switched Entero Therapeutics white as a sheet. The lender got Entero to repay i...

Exelixis falls ADC after deciding it's no match for Tivdak

.Exelixis is actually surrendering on its own cells variable (TF)- targeting antibody-drug conjugate...

Relay loses interest in SHP2 prevention after Genentech leaves behind

.3 full weeks after Roche's Genentech device walked away from an SHP2 inhibitor deal, Relay Therapy ...

Stoke's Dravet syndrome med released of predisposed clinical hold

.Stoke Therapeutics' Dravet disorder medication has actually been devoid of a partial grip, getting ...

Fierce Biotech's Gabrielle Masson shows Strong 15 at NYSE

.Fierce Biotech Partner Publisher Gabrielle Masson showed the 2024 lesson of Tough 15 winners on the...

Daiichi pays Merck $170M to form lung cancer T-cell engager contract

.Merck &amp Co. has actually promptly made back several of the costs of its own Spear Therapeutics p...